Zimmer Biomet (ZBH)
Technical, fundamental, and sentiment analysis with recent related videos.
ZBH rates Bullish overall. The fundamental read is neutral: the company passes 5 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Grey zone (Altman Z = 2.44); revenue is growing about 5.8% per year; net income is growing about 102.9% per year. The technical picture is bullish: price is 8.2% above the 200-day moving average; 3.8% above the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is bullish (composite 74/100), based on 8 news articles from recent coverage.
Revenue 3-year avg +5.8%. Net income 3-year avg +102.9%.
Price vs 20DMA +6.9%. RSI 64.19. Bollinger state: Inside Bands.
Composite score 74/100 from the AI judge, based on 8 news items, 0 television segments, and 0 videos.
Latest Market Read
Fundamental sits Neutral: revenue averaged 5.8 percent per year while reported net income shows a 102.9 percent three-year average, but recent net-income weakness keeps the Fundamental label at Neutral. Technical is Bullish, price is 6.9 percent above the 20-day moving average (20DMA), the Relative Strength Index (RSI), a momentum reading, is 64.2, and the stock trades inside the Bollinger Bands (a volatility channel). Sentiment is Bullish with a 74/100 composite. The overall Bullish rating reflects two Bullish signals and one Neutral.
Recent news: Coverage is largely positive centered on product and partnership momentum: Zimmer Biomet extended its multi-year exclusive distribution deal with Think Surgical for the TMINI handheld robotic knee system, launched ROSA Knee with OptimiZe in India, and rolled out its first robotic shoulder replacement which coincided with a stock uptick. Sources are mostly aligned on robotics-driven growth, while some analyst coverage is neutral ('equal weight'/'hold') and comparative pieces raise valuation and competitive questions.
Latest Videos
- No qualified videos yet.